Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 1
1985 1
1994 1
1995 1
1998 2
2003 2
2004 1
2005 3
2006 1
2008 4
2009 3
2010 4
2011 6
2012 5
2013 1
2014 2
2015 3
2016 9
2017 5
2018 4
2019 6
2020 6
2021 6
2022 4
2023 2
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Squamous Cell Carcinoma"
Page 1
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Waqar SN, et al. Clin Lung Cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33221175 Free PMC article. Clinical Trial.
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). PATIENTS AND METHODS: Patients with previously trea …
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c- …
Pembrolizumab-induced agranulocytosis.
Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M. Fernández Martínez V, et al. J Oncol Pharm Pract. 2024 Jun;30(4):767-771. doi: 10.1177/10781552241228774. Epub 2024 Jan 30. J Oncol Pharm Pract. 2024. PMID: 38291678
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy. ...Depending on bone marro …
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with program …
NUT carcinoma of the lung.
Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A. Lantuejoul S, et al. Semin Diagn Pathol. 2021 Sep;38(5):72-82. doi: 10.1053/j.semdp.2021.06.005. Epub 2021 Jun 16. Semin Diagn Pathol. 2021. PMID: 34176698 Review.
The differential diagnoses include basaloid carcinoma of the lung, small cell carcinoma, thymic carcinoma (basaloid variant), SMARCA4_deficient thoracic sarcoma, other NUTM1 rearranged undifferentiated tumors, small round cell tumors, non …
The differential diagnoses include basaloid carcinoma of the lung, small cell carcinoma, thymic carcinoma …
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA. Asmar R, et al. Cancer J. 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. Cancer J. 2015. PMID: 26389763 Review.
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of checkpoint inhibition has become an important treatment option for patients with advanced non-small cell lung cancer, playing a …
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of c …
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y. Kudo T, et al. Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15. Lancet Oncol. 2017. PMID: 28314688 Clinical Trial.
METHODS: We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the oesophagus refractory or intolerant to fluoropyrimidine-b …
METHODS: We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced squamous-cell carcinom …
Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis.
Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH, Vermeer PD. Vermeer DW, et al. Oncotarget. 2016 Apr 26;7(17):24194-207. doi: 10.18632/oncotarget.8254. Oncotarget. 2016. PMID: 27013584 Free PMC article.
Human papillomavirus induced (HPV+) cancer incidence is rapidly rising, comprising 60-80% of oropharyngeal squamous cell carcinomas (OPSCCs); while rare, recurrent/metastatic disease accounts for nearly all related deaths. ...We characterize an immune competent recu …
Human papillomavirus induced (HPV+) cancer incidence is rapidly rising, comprising 60-80% of oropharyngeal squamous cell carci …
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Meshulami N, et al. Clin Lung Cancer. 2023 Jul;24(5):401-406. doi: 10.1016/j.cllc.2023.03.014. Epub 2023 Apr 25. Clin Lung Cancer. 2023. PMID: 37208221 Review.
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 85% of lung cancer tumors. ...We encourage future researchers to analyze the predictability of PD-L1 biomarker expression separately for s …
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 85% of lung …
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M. Sato H, et al. Cancer Treat Res Commun. 2021;26:100290. doi: 10.1016/j.ctarc.2020.100290. Epub 2020 Dec 26. Cancer Treat Res Commun. 2021. PMID: 33373900 Free article.
INTRODUCTION: Liver metastasis has not been sufficiently evaluated in lung cancer so far. We retrospectively analyzed the distant metastasis of Non-squamous non-small cell lung cancer (NSQ-NSCLC), including liver metastasis, and association between …
INTRODUCTION: Liver metastasis has not been sufficiently evaluated in lung cancer so far. We retrospectively analyzed the distant met …
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.
Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. Ge M, et al. J Neurooncol. 2017 Nov;135(2):413-418. doi: 10.1007/s11060-017-2590-x. Epub 2017 Aug 5. J Neurooncol. 2017. PMID: 28780743
Lung cancer is the leading cause of cancer death in men and women worldwide. Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. ...The EGFR mutation status of primary lesions was detected using the amplification …
Lung cancer is the leading cause of cancer death in men and women worldwide. Brain metastasis (BMs) of non-small cell lung …
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O'Leary B, Braña I, Harrington KJ. Jiménez-Labaig P, et al. Cancer Treat Rev. 2024 Jul;128:102772. doi: 10.1016/j.ctrv.2024.102772. Epub 2024 May 26. Cancer Treat Rev. 2024. PMID: 38820656
INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. ...There were 13 ADC (n = 343) a …
INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) an …
79 results